The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.
about
Human cytomegalovirus resistance to antiviral drugsDisparities in the Magnitude of Human Immunodeficiency Virus-related Opportunistic Infections Between High and Low/Middle-income Countries: Is Highly Active Antiretroviral Therapy Changing the Trend?Comparative radiological features of disseminated disease due to Mycobacterium tuberculosis vs non-tuberculosis mycobacteria among AIDS patients in Brazil.Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.Pneumocystis carinii activates the NF-kappaB signaling pathway in alveolar epithelial cells.Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort studyDisparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patientsHow well do clinicians estimate patients' adherence to combination antiretroviral therapy?Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.Etiology and evaluation of diarrhea in AIDS:a global perspective at the millennium.Gene therapy targeting HIV entry.Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD.Role of human cytomegalovirus genotype polymorphisms in AIDS patients with cytomegalovirus retinitis.Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection.New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposureCulture, myths and panic: Three decades and beyond with an HIV/AIDS epidemic in Zimbabwe.Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy.Discontinuing prophylaxis for opportunistic infection: guiding principles.Dermatologic manifestations of underlying infectious disease among illicit injection-drug users.Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.Highly active antiretroviral therapy for critically ill HIV patients: A systematic review and meta-analysis.Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.Ocular surface squamous neoplasia in HIV-infected patients: current perspectives.Anterior segment and external ocular disorders associated with HIV infections in the era of HAART in Chiang Mai University Hospital, a prospective descriptive cross sectional study.The changing epidemiology of HIV infection: new challenges for HIV palliative care.
P2860
Q24556634-E5C3CB12-D401-4A83-AB90-EC5F48130C50Q26752860-E8EC14AE-956C-4067-A100-07A958F1EB67Q33321960-B0302005-BE38-47DC-8446-C90C9E6187CAQ33680480-044EAACB-E632-45F0-AD07-CF7FBAEB3E77Q33768874-598123F2-9727-49B1-B2E4-79769D65B4CBQ33894498-E84B7BCA-89AA-41B1-8A6E-BD3FE97CE218Q34621738-F7492450-EAF3-4655-9569-4E57D142D570Q34732022-090CCA6D-13F2-405C-8512-C64E58D9ECF3Q34742740-3F10B5C0-40AC-421A-91C6-B3F11F047AA0Q36456737-576BD499-A40E-48D6-99E7-18C1FDE2DC46Q36491860-AB2794A1-7E57-4980-B04C-263958E4CFA7Q37673157-4F4841D1-E9A5-4D04-9945-776EC7D88152Q38495675-4F3E1097-B43B-400B-83E5-3C1557C70E55Q39336485-4A5F9120-D6BA-49F1-9F73-B51794C3842BQ39591313-8A36CF69-7DA5-4C81-A84E-89E05425B73AQ40348364-5CB3C297-E003-47D2-A567-B84C5395386EQ40560464-88B7310C-A847-4338-87FB-461F903C8B37Q41711925-652BAAF9-98E8-4022-87CF-4F6EEF532E70Q41730934-6CFF006D-F6A6-45A6-8BC0-78FB423FAA0FQ45173357-1240FF4E-CFFA-4BEB-9B95-ADD3EE6ED03BQ45734056-863C2876-7FD4-425C-A4D7-066C8E7DE163Q47152806-A031B3A6-461C-4ABC-8093-9AE960BA0C86Q50664942-C1C325CB-7420-49E4-98E4-987620CBEE91Q52646023-38E35A87-09B9-4C91-BFB8-949348CA5EFEQ54269413-4E2E0CDA-EA67-46A4-ABCF-A02D10F7A92FQ55363467-A8644550-EA9F-454E-B5DF-B64E1DFD175E
P2860
The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
The incidence and spectrum of ...... ted with antiretroviral drugs.
@en
The incidence and spectrum of ...... ted with antiretroviral drugs.
@nl
type
label
The incidence and spectrum of ...... ted with antiretroviral drugs.
@en
The incidence and spectrum of ...... ted with antiretroviral drugs.
@nl
prefLabel
The incidence and spectrum of ...... ted with antiretroviral drugs.
@en
The incidence and spectrum of ...... ted with antiretroviral drugs.
@nl
P2093
P356
P1476
The incidence and spectrum of ...... ted with antiretroviral drugs.
@en
P2093
Forrest DM
Montaner JS
O'Shaughnessy MV
Phillips P
Schechter MT
Seminari E
P304
P356
10.1086/515030
P407
P577
1998-12-01T00:00:00Z